Hologic, Inc. $HOLX Shares Bought by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. increased its position in Hologic, Inc. (NASDAQ:HOLX) by 107.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,207 shares of the medical equipment provider’s stock after buying an additional 16,655 shares during the period. Crossmark Global Holdings Inc.’s holdings in Hologic were worth $2,174,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Hologic by 10.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,776 shares of the medical equipment provider’s stock valued at $2,395,000 after purchasing an additional 3,520 shares during the last quarter. Empowered Funds LLC grew its holdings in Hologic by 27.7% in the 1st quarter. Empowered Funds LLC now owns 17,494 shares of the medical equipment provider’s stock valued at $1,081,000 after buying an additional 3,790 shares during the period. Assetmark Inc. grew its holdings in Hologic by 22.0% in the 2nd quarter. Assetmark Inc. now owns 3,285 shares of the medical equipment provider’s stock valued at $214,000 after buying an additional 593 shares during the period. Resona Asset Management Co. Ltd. increased its stake in shares of Hologic by 39.5% during the 2nd quarter. Resona Asset Management Co. Ltd. now owns 120,165 shares of the medical equipment provider’s stock valued at $7,828,000 after acquiring an additional 34,046 shares during the last quarter. Finally, Savant Capital LLC increased its stake in shares of Hologic by 1.2% during the 2nd quarter. Savant Capital LLC now owns 19,606 shares of the medical equipment provider’s stock valued at $1,278,000 after acquiring an additional 232 shares during the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on HOLX. Weiss Ratings reissued a “hold (c)” rating on shares of Hologic in a research report on Wednesday, January 28th. Morgan Stanley upped their price target on shares of Hologic from $69.00 to $76.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 11th. Evercore downgraded shares of Hologic from an “outperform” rating to an “in-line” rating and cut their price target for the stock from $79.00 to $78.00 in a research note on Monday, January 5th. BNP Paribas Exane lowered shares of Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 price target on the stock. in a report on Friday, November 21st. Finally, Argus downgraded Hologic from a “buy” rating to a “hold” rating in a report on Monday, January 12th. Two research analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $78.42.

Hologic Trading Down 0.0%

Shares of HOLX stock opened at $75.74 on Monday. The company has a quick ratio of 3.32, a current ratio of 4.04 and a debt-to-equity ratio of 0.48. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $75.75. The firm’s 50 day moving average price is $75.04 and its two-hundred day moving average price is $72.44. The stock has a market cap of $16.91 billion, a price-to-earnings ratio of 31.56, a price-to-earnings-growth ratio of 2.25 and a beta of 0.73.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.09 by ($0.05). Hologic had a return on equity of 19.58% and a net margin of 13.18%.The business had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same period in the previous year, the company earned $0.87 EPS. Hologic’s revenue was up 2.5% on a year-over-year basis. On average, analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.